vs
帕可Bio（PACB）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
帕可Bio的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.3倍（$44.6M vs $35.5M），帕可Bio净利率更高（-90.4% vs -304.2%，领先213.8%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 13.8%），帕可Bio自由现金流更多（$-19.9M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 7.3%）
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
PACB vs RXRX — 直观对比
营收规模更大
PACB
是对方的1.3倍
$35.5M
营收增速更快
RXRX
高出667.9%
13.8%
净利率更高
PACB
高出213.8%
-304.2%
自由现金流更多
PACB
多$27.4M
$-47.3M
两年增速更快
RXRX
近两年复合增速
7.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $44.6M | $35.5M |
| 净利润 | $-40.4M | $-108.1M |
| 毛利率 | 37.1% | 59.8% |
| 营业利润率 | -92.3% | -304.8% |
| 净利率 | -90.4% | -304.2% |
| 营收同比 | 13.8% | 681.7% |
| 净利润同比 | -1802.7% | 39.6% |
| 每股收益（稀释后） | $-0.11 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PACBRXRX
| Q4 25 | $44.6M | $35.5M | ||
| Q3 25 | $38.4M | $5.2M | ||
| Q2 25 | $39.8M | $19.2M | ||
| Q1 25 | $37.2M | $14.7M | ||
| Q4 24 | $39.2M | $4.5M | ||
| Q3 24 | $40.0M | $26.1M | ||
| Q2 24 | $36.0M | $14.4M | ||
| Q1 24 | $38.8M | $13.8M |
净利润PACBRXRX
| Q4 25 | $-40.4M | $-108.1M | ||
| Q3 25 | $-38.0M | $-162.3M | ||
| Q2 25 | $-41.9M | $-171.9M | ||
| Q1 25 | $-426.1M | $-202.5M | ||
| Q4 24 | $2.4M | $-178.9M | ||
| Q3 24 | $-60.7M | $-95.8M | ||
| Q2 24 | $-173.3M | $-97.5M | ||
| Q1 24 | $-78.2M | $-91.4M |
毛利率PACBRXRX
| Q4 25 | 37.1% | 59.8% | ||
| Q3 25 | 41.4% | -183.8% | ||
| Q2 25 | 36.9% | -4.9% | ||
| Q1 25 | -3.7% | -48.0% | ||
| Q4 24 | 25.6% | -181.4% | ||
| Q3 24 | 25.0% | 53.7% | ||
| Q2 24 | 16.5% | 36.2% | ||
| Q1 24 | 29.1% | 19.1% |
营业利润率PACBRXRX
| Q4 25 | -92.3% | -304.8% | ||
| Q3 25 | -101.1% | -3327.6% | ||
| Q2 25 | -112.8% | -916.8% | ||
| Q1 25 | -1154.5% | -1297.9% | ||
| Q4 24 | -390.1% | -4042.4% | ||
| Q3 24 | -160.3% | -377.1% | ||
| Q2 24 | -488.3% | -697.4% | ||
| Q1 24 | -209.6% | -698.4% |
净利率PACBRXRX
| Q4 25 | -90.4% | -304.2% | ||
| Q3 25 | -98.9% | -3135.3% | ||
| Q2 25 | -105.4% | -894.2% | ||
| Q1 25 | -1146.8% | -1373.3% | ||
| Q4 24 | 6.0% | -3935.5% | ||
| Q3 24 | -151.9% | -367.5% | ||
| Q2 24 | -481.3% | -676.6% | ||
| Q1 24 | -201.4% | -662.4% |
每股收益（稀释后）PACBRXRX
| Q4 25 | $-0.11 | $-0.17 | ||
| Q3 25 | $-0.13 | $-0.36 | ||
| Q2 25 | $-0.14 | $-0.41 | ||
| Q1 25 | $-1.44 | $-0.50 | ||
| Q4 24 | $-0.44 | $-0.56 | ||
| Q3 24 | $-0.22 | $-0.34 | ||
| Q2 24 | $-0.64 | $-0.40 | ||
| Q1 24 | $-0.29 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $279.5M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $5.3M | $1.1B |
| 总资产 | $784.1M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资PACBRXRX
| Q4 25 | $279.5M | $743.3M | ||
| Q3 25 | $298.7M | $659.8M | ||
| Q2 25 | $314.7M | $525.1M | ||
| Q1 25 | $343.1M | $500.5M | ||
| Q4 24 | $389.9M | $594.4M | ||
| Q3 24 | $471.1M | $427.6M | ||
| Q2 24 | $509.8M | $474.3M | ||
| Q1 24 | $561.9M | $296.3M |
总债务PACBRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益PACBRXRX
| Q4 25 | $5.3M | $1.1B | ||
| Q3 25 | $36.1M | $1.0B | ||
| Q2 25 | $61.5M | $919.1M | ||
| Q1 25 | $91.6M | $933.9M | ||
| Q4 24 | $506.6M | $1.0B | ||
| Q3 24 | $453.1M | $524.6M | ||
| Q2 24 | $492.7M | $584.4M | ||
| Q1 24 | $649.0M | $401.2M |
总资产PACBRXRX
| Q4 25 | $784.1M | $1.5B | ||
| Q3 25 | $803.2M | $1.4B | ||
| Q2 25 | $825.5M | $1.3B | ||
| Q1 25 | $860.8M | $1.3B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.5B | $726.5M | ||
| Q2 24 | $1.5B | $775.9M | ||
| Q1 24 | $1.7B | $557.8M |
负债/权益比PACBRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-19.1M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-19.9M | $-47.3M |
| 自由现金流率自由现金流/营收 | -44.6% | -133.1% |
| 资本支出强度资本支出/营收 | 1.9% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-114.1M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流PACBRXRX
| Q4 25 | $-19.1M | $-46.1M | ||
| Q3 25 | $-18.7M | $-117.4M | ||
| Q2 25 | $-29.4M | $-76.4M | ||
| Q1 25 | $-44.1M | $-132.0M | ||
| Q4 24 | $-30.6M | $-115.4M | ||
| Q3 24 | $-45.5M | $-59.2M | ||
| Q2 24 | $-54.3M | $-82.2M | ||
| Q1 24 | $-75.7M | $-102.3M |
自由现金流PACBRXRX
| Q4 25 | $-19.9M | $-47.3M | ||
| Q3 25 | $-18.8M | $-117.6M | ||
| Q2 25 | $-29.9M | $-79.6M | ||
| Q1 25 | $-45.4M | $-133.8M | ||
| Q4 24 | $-32.3M | $-116.7M | ||
| Q3 24 | $-46.3M | $-63.8M | ||
| Q2 24 | $-55.7M | $-83.4M | ||
| Q1 24 | $-79.6M | $-109.0M |
自由现金流率PACBRXRX
| Q4 25 | -44.6% | -133.1% | ||
| Q3 25 | -48.9% | -2272.5% | ||
| Q2 25 | -75.3% | -413.9% | ||
| Q1 25 | -122.3% | -907.4% | ||
| Q4 24 | -82.3% | -2567.7% | ||
| Q3 24 | -115.7% | -244.6% | ||
| Q2 24 | -154.8% | -578.5% | ||
| Q1 24 | -205.0% | -789.9% |
资本支出强度PACBRXRX
| Q4 25 | 1.9% | 3.5% | ||
| Q3 25 | 0.2% | 4.7% | ||
| Q2 25 | 1.4% | 16.4% | ||
| Q1 25 | 3.7% | 12.4% | ||
| Q4 24 | 4.1% | 28.6% | ||
| Q3 24 | 2.0% | 17.5% | ||
| Q2 24 | 4.1% | 8.2% | ||
| Q1 24 | 10.0% | 48.2% |
现金转化率PACBRXRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -12.93× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
RXRX
暂无分部数据
